GLP-1 Medication Use: Why Many Patients Change Their Prescriptions

By TechnoRapper editorial desk. This is an attributed analysis of the linked source, not original reporting or an independent test.

GLP-1 medication use — Nearly half of U.S. adults who used GLP-1 medications in 2025 reported changing how they took them, often because of cost or availability.

What changed

A CDC analysis of survey responses collected in July and August 2025 found that an estimated 9.8 percent of U.S. adults used a glucagon-like peptide-1 receptor agonist, commonly called a GLP-1 medication. That share represents around 27 million adults, according to the study published in the agency’s Morbidity and Mortality Weekly Report.

The survey also points to a gap between prescriptions and real-world use. Among respondents using GLP-1 drugs, 44 percent said they had taken them differently from the way they were prescribed.

Reported changes included skipping doses, postponing refills and taking a smaller amount than prescribed. The source does not break down how many people used each approach, so the findings describe a broad pattern rather than the frequency of any one change.

To prepare this report, the TechnoRapper editorial desk used the supplied Ars Technica coverage as its source and attributed the study findings to the CDC analysis described there.

Why GLP-1 medication use matters

GLP-1 medicines are used for diabetes and weight loss, and the source describes a growing range of related chronic health conditions, including cardiovascular disease and obstructive sleep apnea. When patients alter a prescribed dose or schedule, their treatment no longer follows the plan their clinician set.

The survey does not establish what health effects followed from those changes, and it does not show that every adjustment caused harm. It does, however, highlight a practical challenge: a treatment’s real-world effectiveness and safety may depend partly on whether patients can obtain and use it as prescribed.

Cost and availability were central in the responses. More than half of those who reported changing their use said they did so because of one or both barriers, suggesting that adherence is not only a matter of patient choice.

Analysis: For patients and clinicians, the findings make access worth discussing alongside a prescription. A missed dose, delayed refill or smaller dose may signal that the prescribed plan is difficult to maintain, though this survey alone cannot explain any individual patient’s circumstances.

Who is affected

The findings concern U.S. adults who reported using a GLP-1 medication in 2025. The CDC researchers analyzed responses from more than 8,000 adults; the estimate of around 27 million users is a population estimate drawn from that survey, not a count of prescriptions or people verified through medical records.

People who modified their use reported different reasons, but the source says cost and availability accounted for more than half of those changes. That makes patients facing barriers to obtaining their medication a key group in the results, while the survey does not identify specific medicines, prices or supply conditions.

Age patterns stood out in the cost responses. Among adults aged 14–39 who changed their use, 58 percent cited cost as a barrier, compared with 20 percent of adults aged 65 or older who said the same.

Those figures compare the share citing cost within each age group of people who modified their use; they do not mean that 58 percent of all younger GLP-1 users changed their medication because of cost. The source also does not explain why the groups differed, so the numbers should not be treated as evidence of a particular cause.

What to watch next

Readers should watch for further detail from the CDC or other research on how often patients change doses, skip medication or delay refills, and how those patterns relate to access. The supplied account reports survey findings, but it does not provide individual treatment outcomes or establish cause and effect.

Cost and availability deserve particular attention in follow-up reporting because respondents cited them as reasons for changing use, and cost concerns varied by age. More information would be needed to determine which access barriers matter most and whether the reported patterns persist.

For anyone taking a GLP-1 medication, the study is not individualized medical advice. Its findings describe population-level reports; the source does not recommend a particular dose or treatment change.

Frequently asked questions

How many U.S. adults used GLP-1 medications in 2025?
The CDC analysis estimated that 9.8 percent of U.S. adults used a GLP-1 medication in 2025, or around 27 million people. The estimate came from survey responses collected in July and August.

How many GLP-1 users changed how they took their medication?
In the survey, 44 percent of GLP-1 users said they used the medication differently from how it was prescribed. Examples included skipping doses, delaying refills and taking smaller doses.

Why did some people change their GLP-1 use?
More than half of respondents who changed their use cited cost or availability. Cost was cited by 58 percent of adults aged 14–39 who modified their use and by 20 percent of adults aged 65 or older who did so.

Related on TechnoRapper

• Kalshi advisory role: Kalshi Ends Donald Trump Jr.’s Advisory Role After
• AI takeover: OpenAI Board Member Warns AI Could Take Control of Human Decisions
• Windows SignDrop Flaw Lets Local Users Reach System-Level Access
• Microsoft 365 Outage Continues as Email Protection Window Reaches 48 Hours
• Slate Auto Screenless GPS: Slate Auto’s Screenless GPS Brings the Road Atlas

Inspired by: Ars Technica

How we used the source: facts, quotes, and numbers in this article come only from that Inspired by link. We added structure, search intent, and reader context. We did not independently verify the reporting.